Everolimus is an mTOR inhibitor that targets PTEN and TMEM127, and the resultant inhibitory effect is more pronounced in cancers with high METTL3 expression, albeit small molecule inhibitors of METTL3 are currently under investigation (114). The gene discussed is MTOR; the disease is cancer.